| oxaliplatin / Generic mfg. |
NCT00040820: Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer |
|
|
| Completed | N/A | | US | oxaliplatin | Roswell Park Cancer Institute | Colorectal Cancer | 08/03 | 03/04 | | |
NCT00250029: Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen |
|
|
| Completed | N/A | 30 | US | Oxaliplatin, XELOX (oxaplatin+capecitabine) | New Mexico Cancer Care Alliance | Colonic Diseases, Cancer | 09/05 | 03/06 | | |
NCT00448838: Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
|
|
| Completed | N/A | 42 | US | Cetuximab, C-225, Gemcitabine Hydrochloride, Gemcitabine HCl, Oxaliplatin | University of Miami | Pancreatic Cancer | 08/07 | 03/11 | | |
NCT01310972: Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX |
|
|
| Completed | N/A | 6 | RoW | Registry | King Faisal Specialist Hospital & Research Center | Colon Cancer | 09/07 | 09/07 | | |
NCT00039611: Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | N/A | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | | 10/07 | | |
NCT00897819: Studying DNA and Outcome in Patients With Advanced Colorectal Cancer Treated With Fluorouracil and Oxaliplatin With or Without Bevacizumab on Clinial Trial E-3200 |
|
|
| Completed | N/A | 350 | NA | DNA methylation analysis, loss of heterozygosity analysis, microsatellite instability analysis, laboratory biomarker analysis | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Colorectal Cancer | 01/08 | 01/08 | | |
NCT00430027: Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma |
|
|
| Terminated | N/A | 8 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Cetuximab, Erbitux | University of Colorado, Denver, Bristol-Myers Squibb, Sanofi | Esophageal Adenocarcinoma | 08/08 | 08/08 | | |
NCT00729677: Delayed Nausea and Vomiting in Patients With Colorectal Cancer Receiving Oxaliplatin |
|
|
| Completed | N/A | 64 | US | | Beth Israel Medical Center | Colorectal Cancer, Nausea, Vomiting | 11/08 | 12/08 | | |
NCT00131586: Cisplatin, Carboplatin, and Oxaliplatin Interactions With Plasma Proteins |
|
|
| Terminated | N/A | 100 | Canada | | AHS Cancer Control Alberta | Lung Cancer, Colorectal Cancer | 02/09 | 02/09 | | |
NCT00885950: Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants |
|
|
| Completed | N/A | 80 | Europe | | Maastricht University Medical Center | Sinusoidal Obstruction Syndrome, Colorectal Liver Metastases | 12/09 | 06/10 | | |
NCT02550119: Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy |
|
|
| Terminated | N/A | 19 | US | Aprepitant, Emend, L-754030, MK-0869, ONO-7436, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Dolasetron Mesylate, Anzemet, MDL 73,147EF, Placebo, PLCB, sham therapy | University of Southern California, National Cancer Institute (NCI) | Malignant Digestive System Neoplasm, Nausea and Vomiting | 04/10 | 04/10 | | |
| Completed | N/A | 26 | Europe | | University of Oxford, oxBRC, Vodafone UK Foundation, Centre for Statistics in Medicine, Oncology Clinical Trials Office (OCTO, Oxford) | Metastatic Colorectal Cancer, Metastatic Breast Cancer | 12/10 | 04/11 | | |
NCT00826800: Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer |
|
|
| Terminated | N/A | 2 | US | FOLFOX and bevacizumab | Memorial Sloan Kettering Cancer Center, Genentech, Inc. | Colon Cancer | 01/11 | 01/11 | | |
NCT01366118: Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients |
|
|
| Completed | N/A | 16 | Europe | Therapeutic target tailored chemotherapy, Therapeutic targets, Oxaliplatin, CPT-11, 5-FU | Grupo Hospital de Madrid | Rectal Cancer | 04/11 | 04/11 | | |
NCT01437618: First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 15 | Europe | FOLFOXIRI plus bevacizumab | Azienda Ospedaliero, Universitaria Pisana | Metastatic Colorectal Cancer | | 05/11 | | |
|
NCT01339832: An Observational Study of Xeloda (Capecitabine) and Oxaliplatin Prior and Concurrent To Preoperative Pelvic Radiotherapy in Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 51 | Europe | | Hoffmann-La Roche, Sanofi | Colorectal Cancer | 12/11 | 12/11 | | |
NCT01679054: Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong |
|
|
| Completed | N/A | 58 | RoW | | Vivian Wing Yan Lee, Hoffmann-La Roche, Princess Margaret Hospital, Hong Kong, Pamela Youde Nethersole Eastern Hospital | Gastric Cancer | 07/12 | 07/12 | | |
NCT01134666: An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Terminated | N/A | 165 | RoW | Cetuximab, Erbitux | Merck KGaA, Darmstadt, Germany, Merck Ltd., India | Colorectal Neoplasms | 07/13 | 08/14 | | |
NCT00462501: Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer |
|
|
| Completed | N/A | 35 | US | bevacizumab, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Genentech, Inc. | Colorectal Cancer | 02/14 | 02/14 | | |
NCT01399190: An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer |
|
|
| Completed | N/A | 68 | Europe | Bevacizumab, Avastin®, Capecitabine, Xeloda®, Oxaliplatin, Eloxatin™ | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
NCT02063412: Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens |
|
|
| Withdrawn | N/A | 0 | NA | | Vivian Wing Yan Lee, Hoffmann-La Roche, Queen Elizabeth Hospital, Hong Kong, Princess Margaret Hospital, Hong Kong | Gastric Cancer | 04/14 | 04/14 | | |
NCT01760694: Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer |
|
|
| Terminated | N/A | 6 | US | Multi-Modality; IORT, Surgery, Radiation, Chemotherapy, Intraoperative Radiation Therapy (IORT), Chemotherapy: FOLFIRINOX, Oxaliplatin, Irinotecan, 5-FU, Leucovorin, Surgery: Resectable or Marginally Resectable | Southwestern Regional Medical Center | Pancreatic Cancer | 07/14 | 07/14 | | |
NCT02312284: Observational Study on the Patients With Rectal Cancer |
|
|
| Completed | N/A | 3995 | RoW | | Chinese Academy of Medical Sciences | Rectal Cancer, Adjuvant Chemoradiotherapy, Neoadjuvant Chemoradiotherapy, Adjuvant Chemotherapy, Surgery | 11/14 | 11/14 | | |
NCT01801085: Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens |
|
|
| Terminated | N/A | 21 | RoW | | Vivian Wing Yan Lee, Hoffmann-La Roche, Queen Elizabeth Hospital, Hong Kong, Princess Margaret Hospital, Hong Kong | Colorectal Cancer | 12/14 | 12/14 | | |
NCT02425930: The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer |
|
|
| Completed | N/A | 85 | RoW | gastrectomy plus D2 lymphadenectomy, D2 surgery, S-1+Oxaliplatin, SOX regimen | First Affiliated Hospital, Sun Yat-Sen University | Gastric Cancer, Complement Component Deficiency, Surgery | 02/15 | 04/15 | | |
NCT01442155: An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer |
|
|
| Completed | N/A | 74 | Europe | Capecitabine, Xeloda, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 04/15 | 04/15 | | |
SIRFLOX, NCT00724503: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer |
|
|
| Completed | N/A | 530 | US, Europe, RoW | SIR-Spheres yttrium-90 microspheres, mFOLFOX6m + SIRT, SIR-Spheres Y-90 microspheres, Systemic chemotherapy (FOLFOX), mFOLFOX6 | Sirtex Medical | Colorectal Cancer, Colorectal Carcinoma, Liver Metastases | 05/15 | 05/15 | | |
|
|
|
|
NCT02192983: A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer. |
|
|
| Completed | N/A | 242 | RoW | | Tianshu Liu | Locally Advanced Gastric Cancer | 05/15 | 05/15 | | |
NCT01209962: A Pilot Study of Diffusion MRI in the Assessment of Pancreatic Tumor Response |
|
|
| Completed | N/A | 20 | US | | University of Michigan Rogel Cancer Center | Pancreatic Cancer | 05/15 | 05/15 | | |
NCT01596634: Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy |
|
|
| Completed | N/A | 12 | US | questionnaire administration, quality-of-life assessment, quality of life assessment, laboratory biomarker analysis, bovine lactoferrin | Wake Forest University Health Sciences, National Cancer Institute (NCI) | Colorectal Cancer, Dysgeusia, Oral Complications of Chemotherapy | 08/15 | 10/15 | | |
NCT01422993: Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy |
|
|
| Completed | N/A | 4 | US | 12 Week Exercise Program | H. Lee Moffitt Cancer Center and Research Institute, ONS Foundation | Neuropathy, Gastrointestinal Cancer | 04/16 | 12/16 | | |
NCT01472250: A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China |
|
|
| Completed | N/A | 498 | RoW | Clinical chemo-drugs | Peking University | Advanced Gastric Cancer | 07/16 | 07/16 | | |
NCT01364376: S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma |
|
|
| Completed | N/A | 583 | RoW | S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium | Zhejiang University | Stomach Neoplasms | 08/16 | 08/16 | | |
NCT02412683: Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer |
|
|
| Completed | N/A | 50 | Europe | oxaliplatin | Jenny Drott | Colorectal Neoplasms | 09/16 | 09/16 | | |
mEGA, NCT02358863: Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach |
|
|
| Terminated | N/A | 13 | US | Modified FOLFOX6, Oxaliplatin, Eloxatin, Leucovorin, 5-FU, 5-Flourouracil, Docetaxel/Capecitabine, Taxotere, Xeloda, Cisplatin/Irinotecan, Platinum, CPT-11, Camptosar, Cisplatin/Docetaxel, IRI/EPI, Irinotecan, Epirubicin, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel | Georgetown University | Esophageal Cancer, Gastric Cancer | 11/16 | 11/16 | | |
NCT02560740: A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy |
|
|
| Terminated | N/A | 9 | RoW | PerOx Quench, PerOx Quench Placebo | SMR Biotech Co., Ltd. | Colorectal Cancer, Advanced Gastric Cancer, Neuropathy | 11/16 | 11/16 | | |
ATOM ES, NCT01834014: Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
|
|
| Completed | N/A | 110 | Japan | Bevacizumab, Avastin, Cetuximab, Erbitux, L-OHP, Oxaliplatin, l-LV, Levofolinate, 5-FU, Fluorouracil | EPS Corporation | Liver Metastasis, Colorectal Cancer | 03/17 | 03/17 | | |
NCT02836977: Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection |
|
|
| Active, not recruiting | N/A | 400 | RoW | tegafur-uracil, UFUR | Kaohsiung Medical University Chung-Ho Memorial Hospital | Stage III Colon Cancer | 03/17 | 02/24 | | |
NCT01506167: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) |
|
|
| Completed | N/A | 719 | Europe | Bevacizumab, Avastin®, Capecitabine/Oxaliplatin, Fluorouracil/Folinic Acid/Oxaliplatin, Capecitabine, Fluorouracil/Folinic Acid/Irinotecan, Fluorouracil +/- Folinic Acid | Hoffmann-La Roche | Colorectal Cancer | 03/17 | 03/17 | | |
NCT01163305: PET-CT and Circulating Tumor Cells in Colorectal Cancer |
|
|
| Completed | N/A | 84 | RoW | Chemotherapy | Chinese University of Hong Kong | Colorectal Cancer, Metastasis | 04/17 | 04/17 | | |
AVACONT, NCT02305615: An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC) |
|
|
| Completed | N/A | 300 | Europe | Bevacizumab, Avastin, Chemotherapy | Hoffmann-La Roche | Colorectal Cancer | 12/17 | 12/17 | | |
NCT02969122: Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor |
|
|
| Recruiting | N/A | 59 | RoW | standard gastrectomy with D2 lymphadenectomy, hyperthermic intraperitoneal chemotherapy, HIPEC, Extensive intraperitoneal lavage, EIPL, Preoperative chemotherapy, Postoperative chemotherapy | Peking University | Stomach Neoplasm | 12/23 | 12/23 | | |
